3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
3
NET
1
Gastrointestinal
1
CNS
1
Conditions
Neuroendocrine Tumors
12
Gastro-enteropancreatic neuroendocrine tumor
4
Carcinoid Tumor
3
Neoplasms
2
Carcinoma, Islet Cell
2
Adenoma, Islet Cell
2
Vipoma
1
Somatostatinoma
1
Serotonin Syndrome
1
Pancreatic Neuroendocrine Tumor G2
1
Neoplastic Cells, Circulating
1
Neoplasm Metastasis
1
Insulinoma
1
Glucagonoma
1
Gastrinoma
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Acromegaly
1
Interventions
pasireotide
1
lanreotide
1
Octreotide
1
Cabergoline
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Acromegaly
×
Octreotide
×
NET
×
Clear all
NCT05364944
2025-11-17
OXTEND-01
Debiopharm International SA
Phase 1
Terminated
19 enrolled